USA flag logo/image

An Official Website of the United States Government

OTF Transistor Microarray for Cancer Diagnosis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70744
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
CA110960
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Agave BioSystems, Inc.
P.O. Box 100 Ithaca, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: OTF Transistor Microarray for Cancer Diagnosis
Agency: HHS
Contract: 1R43CA110960-01
Award Amount: $99,617.00
 

Abstract:

DESCRIPTION (provided by applicant): In response to the solicitation for development of nanotechnologies to improve cancer diagnosis by NCI, Agave BioSystems, in collaboration with Dr. George Malliaras, of the Department of Materials Science and Engineering at Cornell University, proposes to construct a novel organic semiconductor-based DNA microarray system for the diagnosis of cancer that will have a theoretical detection limit of a single copy of target. This detection system will depend on changes in current across an organic thin film transistor (OTFT) induced by the target molecule. Current microarray technologies are limited by the sensitivity and dynamic range of fluorescence detection, photobleaching, and the expense of incorporating fluorescent molecules into the assay. The OTFT is not bound by these restrictions, making the device more sensitive and cost effective than standard microarrays. In addition, we propose to integrate microfluidics with the DNA array thus adding the advantage of small sample volumes, greater sensitivity and the ability to automate the assay. Microfluidics will facilitate the cancer diagnosis by decreasing the quantity of original sample necessary for detection and providing a user friendly format to increase the reproducibility and reliability of the assay. The promise of the microfluidic OTFT microarray is the classification of cancer to increase the efficacy and minimize the toxicity of cancer treatments.

Principal Investigator:

Joel S. Tabb
6072720002
JTABB@AGAVEBIO.COM

Business Contact:

Noe Salazar
5126711369
NSALAZAR@AGAVEBIO.COM
Small Business Information at Submission:

AGAVE BIOSYSTEMS
AGAVE BIOSYSTEMS BOX 80010 AUSTIN, TX 78708

EIN/Tax ID: 161551819
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No